Physician profile
Grishma Parikh
NPI 1649210345
$5,138.84
in general payments reported to CMS, 2019-2025
40 companies · $1,111 in 2025
The $1,111 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $140 · 2020: $103 · 2021: $675 · 2022: $1,147 · 2023: $946 · 2024: $1,016 · 2025: $1,111.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,929 · Education: $85.00 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,929.03 |
| Education | $85.00 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $855.13 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $533.65 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $380.81 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Mannkind Corporation | $335.01 | 2022-2025 | Afrezza |
| Dexcom, INC. | $275.67 | 2021-2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $240.15 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $239.89 | 2019-2023 | Farxiga |
| Amgen INC. | $233.60 | 2021-2025 | Tepezza, Evenity, Prolia |
| Abbvie INC. | $233.17 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $217.81 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Medtronic, INC. | $178.55 | 2021-2025 | Minimed 780g |
| Amneal Pharmaceuticals LLC | $155.71 | 2021-2025 | Unithroid |
| Corcept Therapeutics | $150.51 | 2024-2025 | Korlym |
| Amarin Pharma, INC. | $138.37 | 2019-2022 | |
| Cequr Corporation | $109.59 | 2021-2024 | Cequr Simplicity |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grishma Parikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.